HCW Biologics Inc.

HCWBReported to SECin USCIK 0001828673Filings at SEC EDGAR

No score on this page, by design. Everything here is a fact from a public U.S. register: insider filings at the SEC (Form 4), lobbying filings under the Lobbying Disclosure Act, trades reported by members of Congress under the STOCK Act, and fund holdings in 13F filings. Our scores, percentiles and signals run on the Dutch register only, because that is the only register the model has been validated on.

This page is free to read, and it stops after 3 rows. Everything we currently hold fits inside that, so nothing is being held back here today. Reading the whole list, and the full version of each filer's page, is part of the subscription. What that costs is on the pricing page. Already subscribed? Sign in and this page opens in full.

Filings

Most recent filing first: every line of every Form 4 at this company that passed our review, the same lines as on the register. Reported is the day the filing reached the SEC, usually within two business days of the trade. Amounts are in U.S. dollars, as the form states them.

3
Form 4 lines at HCW Biologics Inc., most recent filing first
Filed byTypeValueReportedFiled byValueTypeSharesReported
Wong Hing CChief Executive OfficerOpen-market buy$59,99823,210 sharesJul 31, 2026Wong Hing CChief Executive Officer$59,998Buy · Jul 31Open-market buy23,210Jul 31, 2026
Flowers LeeSVP of Business DevelopmentOpen-market buy$19,9987,736 sharesJul 31, 2026Flowers LeeSVP of Business Development$19,998Buy · Jul 31Open-market buy7,736Jul 31, 2026
GARRETT SCOTT T—Open-market buy$19,9987,736 sharesJul 31, 2026GARRETT SCOTT T$19,998Buy · Jul 31Open-market buy7,736Jul 31, 2026